SANGAMO THERAPEUTICS, INC
Price data unavailable
Track SGMO in your trading journalAbout SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS, INC (SGMO) is a publicly listed company on US equity markets.
SANGAMO THERAPEUTICS INC
The company reports trailing twelve-month revenue of $12.64M and net loss of $31.00M.
Key metrics include a return on equity of 163.5%, a debt-to-equity ratio of -4.16.
Use FINOTAUR to track SGMO's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $12.64M |
| Net Income (TTM) | $-31.00M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 163.52% |
| Debt-to-Equity | -4.16 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Jan 22
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends
- Benzinga·Mar 18
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
- GlobeNewswire Inc.·Feb 21
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
Want real-time analysis on SGMO?
Track it free in your trading journal. Log trades, tag setups, and review your edge.